Boulder, United States
OnKure Therapeutics, founded in 2011 and headquartered in the United States, operates within the Biotechnology, Health and Wellness, and Life Sciences industries. The company is dedicated to discovering and developing best-in-class precision medicines to treat cancer, focusing on biologically validated drivers of the disease.
OnKure has recently secured a substantial $54.00M in a Series C funding round, concluded on May 23, 2023. This investment underscores the strong confidence from prominent investors, including BlackRock, Acorn Bioventures, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Cormorant Asset Management, and Surveyor Capital.
By strategically targeting well-researched cancer drivers, OnKure is positioned to make significant advancements in precision medicine. For investors, this company presents an opportunity to support groundbreaking innovations with the potential to reshape cancer treatment paradigms.
Leaps & Bounds Pediatric Therapy
Therapy Playground